Cornerstone accepts Chiesi proposal after long courtship

Chiesi Farmaceutici will acquire the 42% of outstanding Cornerstone Therapeutics shares that the private Italian pharmaceutical company does not already own for $9.50 per share, valuing the hospital- and specialty market-focused Cornerstone at roughly $252m.